Management of blood pressure in patients with diabetes.

[1]  Walter T Ambrosius,et al.  Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.

[2]  G. Bakris,et al.  Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. , 2010, JAMA.

[3]  G. Bakris,et al.  The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome. , 2010, The American journal of medicine.

[4]  G. Bakris,et al.  Cardiovascular events during differing hypertension therapies in patients with diabetes. , 2010, Journal of the American College of Cardiology.

[5]  J. Couto,et al.  Prevalence of obesity, type II diabetes mellitus, hyperlipidemia, and hypertension in the United States: findings from the GE Centricity Electronic Medical Record database. , 2010, Population health management.

[6]  Li-sheng Liu,et al.  Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial , 2010, Journal of hypertension.

[7]  M. Mitka.  Aggressive lipid, hypertension targeting yields no benefit for some with diabetes. , 2010, JAMA.

[8]  M. Laakso,et al.  Effect of valsartan on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[9]  G. Bakris,et al.  Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial , 2010, The Lancet.

[10]  R. Grimm,et al.  Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. , 2010, American journal of hypertension.

[11]  Rodica Pop-Busui,et al.  Cardiac Autonomic Neuropathy in Diabetes , 2010, Diabetes Care.

[12]  V. Basevi.  Standards of Medical Care in Diabetes—2010 , 2010, Diabetes Care.

[13]  P. Raskin,et al.  Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. , 2009, Journal of the American Society of Nephrology : JASN.

[14]  A. Dominiczak,et al.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. , 2009, Journal of hypertension.

[15]  D. Suh,et al.  Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988–2004 , 2009, Journal of hypertension.

[16]  M. Law,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[17]  G. Mancia,et al.  When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal , 2009, Journal of hypertension.

[18]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[19]  R. Collins,et al.  The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes , 2008, Journal of hypertension.

[20]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[21]  E. Lewis,et al.  Aliskiren combined with losartan in type 2 diabetes and nephropathy. , 2008, The New England journal of medicine.

[22]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[23]  M. Alderman.  New onset diabetes during antihypertensive therapy. , 2008, American journal of hypertension.

[24]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[25]  K. Iwatsubo,et al.  Ambulatory Blood Pressure Variability Is Increased in Diabetic Hypertensives , 2008, Clinical and experimental hypertension.

[26]  M. Yamagishi,et al.  Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. , 2007, American journal of hypertension.

[27]  S. Bangalore,et al.  A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. , 2007, The American journal of cardiology.

[28]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[29]  Bernard J. Gersh,et al.  Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention , 2007, Circulation.

[30]  N. Chapman,et al.  Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension , 2007, Hypertension.

[31]  B. Davis,et al.  Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2006, Archives of internal medicine.

[32]  Y. Sharabi,et al.  Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. , 2006, American journal of hypertension.

[33]  M. Epstein.  Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy , 2006, Nature Clinical Practice Nephrology.

[34]  G. Hitman,et al.  Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS) , 2005, Diabetologia.

[35]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[36]  D. E. Mathis,et al.  Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2005, Archives of internal medicine.

[37]  Steve N Caritis,et al.  Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization , 2004, The New England journal of medicine.

[38]  F. Messerli,et al.  Antihypertensive therapy and new onset diabetes , 2004, Journal of hypertension.

[39]  J. Sowers.  Recommendations for special populations: diabetes mellitus and the metabolic syndrome. , 2003, American journal of hypertension.

[40]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[41]  H. Parving,et al.  Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. , 2003, Diabetes care.

[42]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[43]  M. Pfeffer,et al.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy , 2003, Annals of Internal Medicine.

[44]  C. Palmer,et al.  Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) , 2003, Hypertension.

[45]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[46]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[47]  J. Sowers,et al.  Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. , 2002, Hypertension.

[48]  Y. Sharabi,et al.  Diuretic induced hyponatraemia in elderly hypertensive women , 2002, Journal of Human Hypertension.

[49]  J. Lea,et al.  Diabetes mellitus and hypertension: key risk factors for kidney disease. , 2002, Journal of the National Medical Association.

[50]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[51]  P. Mehler,et al.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.

[52]  L. Niskanen,et al.  Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. , 2001, Diabetes care.

[53]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[54]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[55]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[56]  T. Pischon,et al.  Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain , 2001 .

[57]  T. Hedner,et al.  Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension–2 , 2000, Journal of hypertension.

[58]  U. Goldbourt,et al.  High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? , 2000, Archives of internal medicine.

[59]  G. Bakris,et al.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[60]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[61]  C. Palmer,et al.  Influence of diabetes and type of hypertension on response to antihypertensive treatment. , 2000, Hypertension.

[62]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[63]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[64]  F. Nieto,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .

[65]  J. Staessen,et al.  Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. , 2000, Archives of internal medicine.

[66]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[67]  C. Bulpitt,et al.  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[68]  Philip D. Harvey,et al.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.

[69]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[70]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[71]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[72]  U. Goldbourt,et al.  Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?: A Systematic Review , 1998 .

[73]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[74]  M. Pahor,et al.  Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.

[75]  R. Schrier,et al.  The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. , 1998, The New England journal of medicine.

[76]  G. Bray,et al.  A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. , 1997, The New England journal of medicine.

[77]  G. Bakris,et al.  Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. , 1997, Hypertension.

[78]  B. Davis,et al.  Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996, JAMA.

[79]  E. Grossman,et al.  Diabetic and Hypertensive Heart Disease , 1996, Annals of Internal Medicine.

[80]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[81]  J. Shemesh,et al.  Left ventricular mass in diabetes-hypertension. , 1992, Archives of internal medicine.

[82]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[83]  G. Assmann,et al.  The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. , 1988, American heart journal.

[84]  S. Sullivan,et al.  Book ReviewMyofascial Pain and Dysfunction: The trigger point manual , 1983 .

[85]  M. Blum,et al.  Response to hypoglycemia masked by propranolol. , 1983, The New England journal of medicine.

[86]  P. Bennett,et al.  Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. , 1980, The New England journal of medicine.

[87]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[88]  Alan C. Wilson,et al.  Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. , 2005, The American journal of cardiology.

[89]  C. Perry,et al.  Eplerenone , 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[90]  F. Messerli,et al.  Are calcium antagonists beneficial in diabetic patients with hypertension? , 2004, The American journal of medicine.

[91]  Philip Raskin,et al.  The treatment of hypertension in adult patients with diabetes. , 2002, Diabetes care.

[92]  R. Fogari,et al.  Ambulatory blood pressure monitoring in normotensive and hypertensive type 2 diabetes. Prevalence of impaired diurnal blood pressure patterns. , 1993, American journal of hypertension.

[93]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.